Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol in Acute Ischemic Stroke Treatment
NCT00272454Phase 4Completed
- Sponsor
- Otsuka Holdings
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of cilostazol in ischemic stroke (2 arms), sponsored by Otsuka Holdings. Primary endpoint: Modified Rankin Scale score of 0-2 at 90 days. Started Jan 2006; status: completed.
02
Drugs
cilostazol
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00272454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272454.